Author:
Randhawa Manreet,Jones Robert, ,
Funder
This article is published under the Creative Commons Attribution Non-commercial License.
Publisher
Touch Medical Media, Ltd.
Reference87 articles.
1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.
2. Cancer Research Institute. FDA approval timeline of active immunotherapies. 2020. Available from: www.cancerresearch.org/scientists/immuno-oncology-landscape/fda-approval-timeline-of-active-immunotherapies (accessed 10 August 2020).
3. Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Ann Rev Med. 2019;70:479–99.
4. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Eng J Med. 2015;373:737–46.
5. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–77.